๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 16 Manchester 8 Truro 6 Birmingham 5 Plymouth 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London16 Manchester8 Truro6 Birmingham5 Plymouth5
All 34 cities
Target enrolment
to
16 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Phase 2
99
Bath, London
2026-05-06
Recruiting
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
NCT07187401Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
Regeneron Pharmaceuticals
Phase 1/2
24
Leeds, London
2026-02-11
Recruiting
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
NCT06836609Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals
Phase 1/2
132
London, Harrow
2025-04-28
Recruiting
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT06669247Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2
186
London, Manchester
2024-12-11
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Regeneron Pharmaceuticals
Phase 3
975
Liverpool, York, Bristol, London, Newcastle upon Tyne
2024-10-30
Active, closed
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent ฮฒ-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals
Phase 2
19
London
2024-09-30
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
Glasgow, Birmingham, Cambridge, London
2024-09-11
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals
Phase 1/2
220
London, Manchester
2024-08-07
Active, closed
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459Hemophilia B
Regeneron Pharmaceuticals
Observational
11
Southampton, London
2024-01-17
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Recruiting
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals
Phase 1/2
36
Cambridge, London
2023-06-27
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Study to Assess the Long-term Safety of Dupilumab Administered in Participants โ‰ฅ6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 3
880
London, Manchester, Sheffield
2015-10-15
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.